Johnson & Johnson (NYSE:JNJ) Holdings Raised by Godshalk Welsh Capital Management Inc.

Godshalk Welsh Capital Management Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 2.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 12,446 shares of the company’s stock after purchasing an additional 240 shares during the period. Johnson & Johnson comprises about 1.2% of Godshalk Welsh Capital Management Inc.’s investment portfolio, making the stock its 25th biggest holding. Godshalk Welsh Capital Management Inc.’s holdings in Johnson & Johnson were worth $1,819,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Innealta Capital LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $27,000. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson during the first quarter valued at about $31,000. MFA Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $44,000. Finally, Fairfield Financial Advisors LTD acquired a new stake in Johnson & Johnson in the 2nd quarter worth $46,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $164.82 on Friday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock has a market capitalization of $396.67 billion, a price-to-earnings ratio of 10.28, a PEG ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The business has a 50-day moving average of $161.02 and a 200-day moving average of $154.17.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. TD Securities lowered their target price on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.